See the DrugPatentWatch profile for keytruda

Keytruda, a drug manufactured by Merck & Co., received its initial FDA (Food and Drug Administration) nod for the treatment of advanced melanoma. This approval was granted in September 2014 [1]. Keytruda, also known as pembrolizumab, is a type of immunotherapy that works by blocking the PD-1 pathway, thereby enhancing the body's natural ability to fight cancer cells [2].

The FDA's approval of Keytruda for advanced melanoma was based on the results of a clinical trial, which demonstrated that the drug significantly improved survival rates in patients with this type of skin cancer [1]. Since its initial approval, Keytruda has received additional approvals for the treatment of various other types of cancer, including non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, and microsatellite instability-high (MSI-H) cancer [2].

It is worth noting that, according to DrugPatentWatch.com, Keytruda's patent is set to expire in 2028, which may lead to the introduction of generic versions of the drug [3]. This could potentially increase access to this life-saving treatment and reduce healthcare costs.

In summary, Keytruda received its initial FDA approval for the treatment of advanced melanoma in September 2014. The drug has since received additional approvals for the treatment of various other types of cancer. Keytruda's patent is set to expire in 2028, which may lead to the introduction of generic versions of the drug.

Sources:
[1] "FDA approves new treatment for advanced melanoma." U.S. Food and Drug Administration. <https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-advanced-melanoma>.
[2] "Keytruda (pembrolizumab)." Merck & Co., Inc. <https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf>.
[3] "Keytruda (pembrolizumab) - Patent Expiry and Generics." DrugPatentWatch.com. <https://www.drugpatentwatch.com/Patent/Keytruda-pembrolizumab-Patent-Expiry-and-Generics-1131>.